Fannin/Allterum awarded $2 million SBIR Phase II grant from NIH to advance monoclonal antibody for treating childhood leukemia PRNewswire – July 19, 2023 Allterum Therapeutics completes Series Seed offering, builds team with addition of Philip Breitfeld as Chief Medical Officer PRNewswire – Dec 17, 2020 Allterum Therapeutics granted Orphan Drug Designation and Rare Pediatric Disease Designation for its monoclonal antibody therapy for pediatric leukemia PRWEB – Oct 6, 2020 Allterum Therapeutics closes $2.9 million CPRIT award to develop novel NCI technology for treating pediatric leukemia, initiates drug manufacturing scale-up with FujiFilm Diosynth PRNewswire – April 21, 2020 Anticancer Antibody Receives First Funds for Trial in Leukemia Patients NCI at Frederick – March 19, 2019
